Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need
of effective treatment strategies. Recent advances in sequencing techniques unraveled the …

Activated EGFR signalling drives tumorigenicity in 50% of glioblastoma (GBM). However,
EGFR-targeting therapy has proven ineffective in treating patients with GBM, indicating that …

Cancer diagnosis, prognosis, mymargin and therapeutic response predictions are based on
morphological information from histology slides and molecular profiles from genomic data …

Chimeric antigen receptor (CAR)-T-cell therapy for solid tumors is limited due to
heterogeneous target antigen expression and outgrowth of tumors lacking the antigen …

Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma
is better understood. For the newly diagnosed, the current standard of care is represented by …

Background: Glioblastoma (GBM) is a highly aggressive cancer with poor prognosis that
needs better treatment modalities. Moreover, there is a lack of reliable biomarkers to predict …

Over the past century, treatment of malignant tumors of the brain has remained a challenge.
Refinements in neurosurgical techniques, discovery of powerful chemotherapeutic agents …

Bacopa monnieri has been used for centuries in Ayurvedic medicine, alone or in
combination with other herbs, as a memory and learning enhancer, sedative, and anti …

Glioblastoma multiforme (GBM) is one of the most common, most formidable, and deadliest
malignant types of primary astrocytoma with a poor prognosis. At present, the standard of …